WebDec 8, 2024 · PHILADELPHIA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Passage Bio (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders (CNS), today announced the expansion of its pipeline and provided a progress update on its three clinical programs. WebFeb 24, 2024 · PHILADELPHIA, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 …
Passage Bio Receives MHRA Clinical Trial Authorization for …
WebJan 19, 2024 · Passage Bio, Inc. Study Details Tabular View No Results Posted Disclaimer How to Read a Study Record Study Description Go to Brief Summary: PBGM01 is a … WebMar 15, 2024 · Passage Bio, a Philadelphia-based gene therapy developer, will cut jobs and pare back spending in an effort to save cash and focus resources on three experimental treatments currently in clinical testing. flat roof repair gresham
Passage Bio Doses First Patient in Global Clinical Trial for …
WebPassage Bio is conducting two interventional studies to bring potential treatments to patients and families affected by rare CNS disorders. We Are Evaluating A New Gene … WebDec 10, 2024 · At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless... WebAug 11, 2024 · Aug 11, 2024 Victoria Johnson PBFT02, developed by Passage Bio, is delivered via intra cisterna magna administration to the brain. Passage Bio has dosed the first patient with frontotemporal dementia with granulin mutations (FTD-GRN) with their gene therapy PBFT02 in the phase 1/2 upliFT-D study (NCT04747431). flat roof repair fort lauderdale